Salam Bachour(@SalamBachour) 's Twitter Profileg
Salam Bachour

@SalamBachour

IM resident at @BrighamMedRes| GI with passion for clinical research in IBD | MD MS @CleClinicLCM | @UMNAlumni | 🎾 🏀 🏎 | 🇸🇾 🇺🇸

ID:1288484545277419520

calendar_today29-07-2020 14:40:51

239 Tweets

306 Followers

394 Following

Follow People
Jean-Frederic Colombel(@JeanFredericCo1) 's Twitter Profile Photo

Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy. pubmed.ncbi.nlm.nih.gov/38492903/

account_circle
Jordan Axelrad, MD, MPH(@DrJordanAxelrad) 's Twitter Profile Photo

📢 📢 New American Gastroenterological Association (AGA) guidelines on Fecal Microbiota-Based Therapies 💩💩💩 for Select Gastrointestinal Diseases 📢 📢

➡️ gastrojournal.org/article/S0016-…

🔥🔥A tweetorial for , published in Gastroenterology 🔥🔥

Follow this🧵

account_circle
Salam Bachour(@SalamBachour) 's Twitter Profile Photo

Check out our updates on the recent advances in prediction, prevention, monitoring, and treatment of postoperative Crohn’s disease; highlighting the most recent data over the last 5-10 years!

Thanks to Ben Click for the chance to work on this update!

link.springer.com/article/10.100…

account_circle
Shrinivas Bishu(@IBDimmunology) 's Twitter Profile Photo

Does DLI/type of surgery (🔪) predict anastomotic stricture (AS) in CD? Benjamin Cohen MD MAS Ben Click AJG - The American Journal of Gastroenterology

🟠Caveats. yes. but good question + history.

✅AS = 18% ~3 yrs
✅DLI + type of 🔪 do not predict AS.
🟢this is what I expect in the biologic era.

journals.lww.com/ajg/fulltext/2…

account_circle
IBDJournal & CC360(@IBDJournals) 's Twitter Profile Photo

The advent of numerous MOA's in the IBD landscape lend themselves to unique SE/AE profiles. Shubha Bhat, PharmD & Ben Click provide some stratification of different agents as they relate to different patient specific factors. bit.ly/48rflBb

account_circle
Badr Al-Bawardy(@Badr_AlBawardy) 's Twitter Profile Photo

Press release of the SEQUENCE study is out

⚫️Head-to head phase 3 study of risankizumab vs ustekinumab in anti-TNF exposed patients with Crohn’s disease

⚫️ Risankizumab met both primary endpoints of non-inferiority for clinical remission and superiority of endoscopic remission

account_circle
Rahul S. Dalal, MD, MPH(@RahulSDalalMD) 's Twitter Profile Photo

Our multicenter study comparing effectiveness of vs for UC induction in CGH:

doi.org/10.1016/j.cgh.…

🔑⬆️odds clin response and steroid-free clin remission at 8-16 wks for upa
🔑⬆️odds endo remission within 52 wks for upa

Brigham and Women's GI UNC Gastroenterology

account_circle
Nishu Uppal(@NishantUppal7) 's Twitter Profile Photo

Health care is making Americans poorer. In NEJM, we describe the current burden of medical debt, the history of our health financing system, and solutions to endemic medical debt in the US.

nej.md/3P1X2tc

1/10

Health care is making Americans poorer. In @NEJM, we describe the current burden of medical debt, the history of our health financing system, and solutions to endemic medical debt in the US. nej.md/3P1X2tc 1/10
account_circle
CGH(@AGA_CGH) 's Twitter Profile Photo

Study finds upadacitinib therapy reduces colitis symptoms as early as day 1 of induction treatment. Learn more at ow.ly/La0S50Pv74z

Study finds upadacitinib therapy reduces #ulcerative colitis symptoms as early as day 1 of induction treatment. Learn more at ow.ly/La0S50Pv74z
account_circle